Darren W. Davis, Ph.D.
Founder, President & CEO
Dr. Darren Davis is a biotechnology executive and visionary leader with more than twenty-five years of distinguished biotechnology and clinical translational research experience. Dr. Davis founded ApoCell in 2004 to commercialize innovative “liquid biopsy” solutions that help accelerate the biopharma decision making process for efficient and economical advancement of drug candidates to the regulated clinical market. He achieved global market expansion through the establishment of subsidiary businesses in Europe and China to support the ApoStream technology development and customer demands for its products. Dr. Davis has a successful track record in building high-performing leadership teams with a global services presence. He developed a proprietary rare cell technology, ApoStream, in collaboration with the National Cancer Institute. Dr. Davis is leading a team of scientists and engineers to develop the ApoStream into a point-of-care regulated medical device. He led ApoCell to achieve dynamic growth and recognition, with placement on the “Inc 500 / 5000 List of America’s Fastest Growing Companies” for three consecutive years, the Houston Business Journal’s “Fast 100” and Deloitte’s “Technology Fast 500.” Dr. Davis is the author and co-author of over 100 peer-reviewed publications. Dr. Davis received his doctorate from the University of Texas Health Science Center School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston, TX.
Sue Zhao, M.S.
Scientific Manager & Flow Cytometry Leader
Sue Zhao has over 18 years of experience in multi-color flow cytometry applications for drug development of preclinical and clinical studies. She has designed numerous immunophenotyping and functional biomarker assays for different therapeutic areas. Prior to joining ApoCell in 2010, she worked as a scientist at Pfizer R&D U.S. for 11 years, where she received a number of Pfizer individual performance awards for her contributions in assay design to the Lyrica, CCR2, and Caspase programs. Sue was also recognized for her great impact to the flow cytometry facility at the Translational Biomarker Group from the Department of Drug Safety at Groton, CT, and her support to Pfizer R&D Shanghai. Sue received her Master’s Degree in Immunotoxicology/Pharmacology from the Department of Pharmaceutical Science at the University of Louisiana Monroe. Prior to that, Sue graduated from the College of Pharmacy in Zhejiang University and served as a licensed pharmacist for China FDA-Zhejiang Bureau.
Bill Soller, Ph.D.
Director of Quality Assurance and Compliance (Consultant)
Dr. Soller has broad in-depth senior management experience in product safety, drug, device and dietary supplement development and regulatory matters, clinical and technical sciences associated with FDA product approval/clearance, quality systems management, clinical and health outcomes research, and health policy. Dr. Soller is the CEO of Biomedical Regulatory Consulting and currently manages regulatory programs for drug, device and dietary supplement companies across the USA, and development and assessments/audits of quality management systems for biotech start-ups, clinical research management companies, CROs, and clinical and laboratory sites. Dr. Soller also provides expert advice on drug and device safety and quality to firms representing defense or plaintiff.
Geoff Copper has 12 years of experience in the clinical research field, the majority of which has been as a member of the ApoCell team. In his time at ApoCell, his duties have included laboratory support, sample logistics, business development, and marketing. Since 2014, Geoff has served as the company’s primary project manager where he interfaces with clients and internal and external operational teams. He received his BS in Biochemistry and Cell Biology from Rice University.
Jan Lawler, CPA
Jan Lawler joined ApoCell as Controller in March 2016. With Big Four accounting firm experience, Jan has held financial leadership positions within diverse project-oriented industries such as biotech, petrochemical, industrial construction, and economic development. From 2004 to 2010 Jan served as President/CEO of the Economic Alliance Houston Port Region, leading the regional non-profit organization in its efforts to rebrand and ultimately recruit approximately $320 million dollars of capital investment and grants to the port region during her tenure. A recipient of the Statewide Community Leadership Award from Texas Chemical Council, Jan currently serves on the board for the HCA System’s Bayshore Hospital and Harris County’s Precinct 2 Non-Profit board that provides social assistance to veterans and children at risk. In 2009, Jan was recognized as one of the Women of Distinction by the Bridge Over Troubled Waters, a non-profit that assists women and families in crisis. A graduate of the University of Houston system, Jan holds a Bachelor of Science Degree in Accounting and is licensed as a Certified Public Accountant in Texas.